 This is a triple cohort, open-label pilot study of the safety and antiviral activity of a single infusion of autologous CD4 T cells genetically modified at the CCR5 gene by Zinc Finger Nucleases SB-728mR ZFN Modified CD4 T Cells using electroporated mRNA with or without the prior administration of two different doses of cyclophosphamide. 